ZUG, Switzerland, July 23, 2025 /PRNewswire/ — Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled “Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open Label Randomized Controlled Trial,” was previously presented as a Late-Breaking Clinical Trial (LBCT) at the 2025 ESC-HFA Congress in Belgrade.

The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highlighting the potential of the Cardio-Microcurrent (C-MIC) device—a novel implantable system that delivers low-intensity microcurrent to the failing myocardium.

Study Summary

In this open-label, randomized controlled trial, 70 ambulatory patients with non-ischemic dilated cardiomyopathy, LVEF 25–35%, and NYHA Class III–IV symptoms were randomized 1:1 to receive C-MIC therapy plus guideline-directed medical therapy (GDMT) or GDMT alone. The primary endpoint was the difference in change in LVEF at 6 months. Secondary endpoints included change in NYHA class, 6-minute walk distance (6MWD), and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS).

At six months, patients receiving C-MIC therapy experienced markedly greater improvements than controls across all prespecified endpoints. Left-ventricular ejection fraction (LVEF) rose by an average of 6.6% in the C-MIC group versus 1.5% in the control group, yielding a mean between-group difference of 5.1% (95 % CI 3.1–7.1; p < 0.001). Clinically meaningful functional gains were similarly superior: 84 % of C-MIC patients improved by at least one NYHA class compared with 15 % of controls—a risk difference of 68.9 % (95 % CI 50.6–87.2; p < 0.001). Quality-of-life also benefited, with 75 % of C-MIC patients achieving a ≥5-point increase in KCCQ Overall Summary Score versus 15 % in controls (risk difference 60.0 %, 95 % CI 42.3–77.6; p < 0.001). Finally, nearly half of treated patients (47 %) attained at least a 30 % rise in six-minute-walk distance compared with only 9 % of controls (risk difference 38.3 %, 95 % CI 14.4–62.2; p = 0.002), underscoring consistent benefit across structural, symptomatic, and functional outcomes. The therapy was well tolerated, with no device-related serious adverse events reported.

Author and Investigator Quotes

“This study offers compelling evidence that microcurrent therapy can enhance both cardiac function and patient-centered outcomes in individuals with HFrEF,” said Prof. Jesus E. Rame, co-first author, The Louis R. Dinon MD Professor of Medicine and Surgery and Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease at Thomas Jefferson University. “These findings introduce a promising new therapeutic avenue for patients who remain symptomatic despite receiving optimal medical therapy.” Dr. Rame further noted, “This randomized controlled trial not only demonstrates the efficacy and safety of the therapy in patients with stable, chronic ambulatory heart failure, but also pioneers an entirely novel treatment paradigm aimed at restoring cardiac function in non-ischemic cardiomyopathy.”

“This was a remarkable collaborative effort across all participating sites,” said Prof. Dragana N. Kosevic, co-first author and co-Principal Investigator at Dedinje Cardiovascular Institute, Belgrade. “We observed meaningful improvements in symptoms and functional capacity among our patients—an encouraging sign for broader clinical adoption.”

Prof. Jan Schmitto, Professor of Cardiac Surgery at the Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, co-first author and coordinating investigator of the trial, commented: “These results validate more than a decade of translational work. They suggest that restoring myocardial bioelectric signaling can have a direct and clinically meaningful impact on cardiac performance in patients with advanced heart failure.”

Prof. Stefan D. Anker, senior author and Professor of Cardiology at Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin added: “This is the first randomized trial to demonstrate that low-level microcurrent stimulation can improve both structural heart function and quality of life. It establishes a strong foundation for future studies focused on long-term clinical outcomes.”

“We are thrilled to see the C-MIC II results published in the European Journal of Heart Failure,” said John Brumfield, CEO of Berlin Heals “These findings support our mission to develop breakthrough, bioelectronic therapies for chronic heart failure—targeting the disease at its electrical and cellular roots.”

To access the full publication in European Journal of Heart Failure, please visit https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3763

Disclaimer:

The C-MIC device is investigational and not approved for commercial use in any jurisdiction. Its safety and effectiveness are still under evaluation.

• Recorded Q2’25 consolidated revenue of KRW 1,289.9 billion
• Recorded Q2’25 consolidated operating profit of KRW 475.6 billion
• Solid momentum sustained through capacity ramp-up and stable project execution

INCHEON, South Korea, July 23, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.

“Our second quarter results demonstrate continued strong momentum across our business,” said John Rim, CEO and President of Samsung Biologics. “With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence.”

SECOND QUARTER 2025 RESULTS

Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4.

In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion.

BUSINESS UPDATES

In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients’ manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards.

The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making.

In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry’s greater demands to ultimately maximize corporate value and sustainable growth potential.

On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.

For more information, please visit https://samsungbiologics.com/.

Samsung Biologics Media Contact

Claire Kim, Head of Marketing & Global Communications
cair.kim@samsung.com 

SINGAPORE, July 23, 2025 /PRNewswire/ — Asian markets have continued to demonstrate resilience, even in the face of US tariffs. In a Special Report published today, UOB Asset Management (UOBAM) assesses that Asian markets could even rally if negotiations ahead of the new 1 August deadline result in improved rates relative to those announced in April. The implication here is that investors no longer expect a return to previous trading arrangements but are nevertheless sanguine about the region’s ability to withstand moderate tariffs.

Colin Ng, UOBAM’s Head of Asian Equities, explains, “The majority of Asian economies are likely to recover relatively quickly from the direct impact of US tariffs. A slowdown in exports to the US can be offset by trading with other countries, and in particular, with their Asian neighbours”

“This is because, on the one hand, more and more Asian companies are building globally recognisable brands, and on the other, the Asian consumer base is now large and affluent enough to absorb these products. That is why ASEAN has taken over from the US as China’s biggest trading partner.”

The UOBAM Special Report, entitled “Will US tariffs detail Asia’s growth?” looks at the short- and longer-term implications of US tariffs on seven markets in Asia, including the big exporters such as Korea, Taiwan region and Singapore as well as those more domestically-focused such as Malaysia and Indonesia.

Ng warns that the risk to Asian economies comes instead from the indirect impact of US tariffs, that is. if the tariffs result in a global growth slowdown or a recession. This is turn would cause the global demand for Asian exports to shrink. However, based on the economic data released so far, Ng says this is not UOBAM’s base case.  

Read the full report: https://www.uobam.com.sg/insights/will-us-tariffs-derail-asia-growth.page

About UOB Asset Management

UOB Asset Management Ltd (UOBAM) is a wholly-owned subsidiary of United Overseas Bank Limited. Established in 1986, UOBAM has nearly 40 years of experience in managing collective investment schemes and discretionary funds in Singapore, making us among the largest unit trust managers by assets under management. As of 30 June 2025, we manage 65 unit trusts in Singapore and together with our subsidiaries, oversees S$37.6 billion in clients’ assets.

Headquartered in Singapore, UOBAM has a strong presence across Asia, with business and investment offices in Brunei, Indonesia, Japan, Malaysia, Thailand and Vietnam. Our network includes UOB Islamic Asset Management Sdn Bhd in Malaysia, a joint venture with Ping An Fund Management Company Limited and strategic alliances with partners such as Wellington Management Singapore.

UOBAM is one of the region’s most awarded asset managers, with over 380 awards won. In 2025, we were recognised as the Best Regional Asset Management Company by the Asia Asset Management and previously named Best Asset Management House in Asia – 20 Years in 2023. Our digital innovation has also earned top honours, including Best Digital Wealth Management in Asia^[1] and Best Robo Advisory Initiative^[2] for 3 consecutive years as of 2024.

As a leader in sustainable investing, UOBAM was awarded Best application of ESG in ASEAN^[3] (2023) and has received multiple sustainability accolades in Indonesia and Thailand. Our artificial intelligence capabilities were also recognised with the Most Innovative Application of Artificial Intelligence (ASEAN) for 2 consecutive years^[4].

Connect with us: LinkedIn | Facebook

Akkodis is joining forces with leading European partners to create innovative traffic management solutions that enhance sustainable urban mobility across Europe.

VIENNA, July 23, 2025 /PRNewswire/ — Akkodis, a global digital engineering company and part of the Adecco Group, is proud to participate in the EU-funded FEDORA[1]  project (Federation of Network Optimisation Services, Simulation Foresights, and Data Alchemy for Adaptable, Agile, Secure, and Resilient Multimodal Traffic Management). Coordinated by ERTICO – ITS Europe, the initiative, officially launched on June 1st, brings together a strong consortium of institutions focused on solving today’s pressing mobility challenges.

Traffic management in the EU project FEDORA. Image credit: Akkodis

The FEDORA project addresses key limitations in current traffic management systems, including a lack of orchestration when addressing multi-modal needs in structured integration protocols and in the incorporation of real-world traffic complexities. These gaps have led to suboptimal performance in managing mobility services and a divergence from the EU’s sustainability targets. To tackle these challenges, FEDORA will develop a federated digital platform that enables advanced, real-time sensing and forecasting of transport supply and demand, supporting more efficient, sustainable movement of people and goods.

At the operational level, FEDORA will offer a collaborative data space from which advanced data processes using interconnected service and tools can be developed. It will also focus on the development of advanced traffic management optimization services and a multi-modal simulation environment to create and assess future mobility scenarios. The approach will be validated through six thematic demonstrations in diverse contexts, including Vienna, the Basque Country, Reggio Emilia, Nicosia, Budapest, and Copenhagen, addressing varying urban and rural conditions, infrastructure maturity levels, and multimodal mobility service availability. The demonstration phase is set to start in summer 2026, with Vienna as the first pilot city.

Akkodis brings proven expertise to FEDORA, having previously coordinated the Horizon 2020-funded MobiDataLab project, which advanced data sharing among mobility stakeholders across Europe. The methodologies and cloud-based service platform developed in MobiDataLab now serve as a foundation for FEDORA’s data space and will be expanded as part of the new initiative.

FEDORA is anticipated to deliver several outcomes that will significantly improve the transport network and traffic oversight. It aims to enhance the multimodal transport system, ensuring efficient door-to-door mobility for both passengers and goods. Additionally, the initiative will develop effective solutions for secure data sharing across different transport modes, fostering a dynamic and responsive management framework.

“Akkodis is committed to leveraging its expertise in digital engineering to contribute to the success of the FEDORA project. By collaborating with ERTICO, the City of Vienna, and a strong network of partners, Akkodis aims to improve the efficiency of decarbonized transport solutions in complex environments, promoting their desirability in order to support the EU’s vision for sustainable mobility,” comments Tanguy Deren, Director of Innovation at Akkodis France.

Contacts

Anne Friedrich

SVP, Global Head of Communications, Akkodis
E. anne.friedrich@adeccogroup.com

Meldina Kurti

Director, Business Partner Communications Germany, Akkodis
E. meldina.kurti@akkodis.com

Maria Sole Quaglio

External Communications Manager Germany, Akkodis
E.  maria-sole.quaglio@akkodis.com

About Akkodis

Akkodis is a global digital engineering company and Smart Industry leader. We enable clients to advance in their digital transformation with Consulting, Solutions, Talent, and Academy services. Headquartered in Switzerland and part of the Adecco Group, Akkodis is a trusted tech partner to the world’s industries. We co-create and pioneer solutions that help to solve major challenges, from accelerating the clean energy transition and green mobility, to improving user and patient centricity. Empowered by a culture of inclusion and diversity, our 50,000 tech experts across 30 countries combine best-in-class technologies and cross industry knowledge to drive purposeful innovation for a more sustainable tomorrow. We are passionate about Engineering a Smarter Future Together. akkodis.com | LinkedIn | Instagram | Facebook| X

About The Adecco Group

The Adecco Group is the world’s leading talent company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power the Smart Industry transformation and empower organizations to optimize their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN).  https://www.adeccogroup.com/